Navigation Links
Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
Date:9/7/2011

LAUSANNE, Switzerland, and MALVERN, Pennsylvania, September 7, 2011 /PRNewswire/ --

Debiopharm Group™ (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascenta Therapeutics, Inc. (Ascenta), a privately-held, biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer, have entered into an exclusive worldwide license agreement concerning the development and commercialization of AT-406 (called Debio 1143 by Debiopharm) a small molecule IAP inhibitor currently in phase I development. By targeting inhibitors of apoptosis proteins, AT-406 (or Debio 1143) can induce cancer cell death and/or potentiate the efficacy of other treatments and is expected to be effective in the treatment of various cancers in combination with anti-cancer therapies.


"We are very excited about this collaboration with Ascenta Therapeutics. This company has an impressive scientific team and expertise in the field of apoptosis", said Dr Rolland-Yves Mauvernay, president and founder of Debiopharm S.A., who added "it should be possible to combine AT-406 (or Debio 1143) with other pro-apoptotic agents, which can potentially bring huge benefits to patients by enhancing the efficiency of the treatment."

"Ascenta is pleased to form this partnership with Debiopharm, a company that has demonstrated a commitment to and expertise in the development of medicines to help cancer patients", noted Dr. Mel Sorensen, President and CEO of Ascenta.

About AT-406

AT-406 is an orally available small molecule that neutralizes major inhibitors of apoptosis. Apoptosis, or "programmed cell death," is a precisely regulated, complex process ensuring that defective, damaged or superfluous cells are eliminated. Evasion of apoptosis is a hallmark of cancer, enabling cancer cells to live indefinitely and grow uncontrollably. Most current cancer therapies
'/>"/>

SOURCE The Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Japanese Cancer Association and Debiopharm Honour Japanese Research
2. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
5. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
6. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
7. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
8. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
9. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
10. Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010
11. INC Research and Debiopharm Group(TM) Announce Strategic Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015 CytomX, a ... cancer, today announced that Sean McCarthy , D. ... Suisse Antibody Day in New York ... Dr. McCarthy will present an overview of CytomX,s Probody ... drug conjugate programs. About CytomX Therapeutics ...
(Date:5/5/2015)... 2015   Tocagen Inc. , a clinical-stage ... Parkinson , M.D., a venture partner at New ... board of directors of Tocagen. Dr. Parkinson has ... clinical development, including leading clinical activities at Amgen ... the cancer therapeutics Gleevec®, Femara®, Zometa®, Kepivance® and ...
(Date:5/5/2015)... College Station, TX (PRWEB) May 05, 2015 ... Pfizer were announced last week as recipients of ... Technology Innovation in recognition of their Portable, Continuous, ... system that integrates a small footprint, continuous processing ... GMP modules) to process API powders and inactive ...
(Date:5/5/2015)... 2015 Synedgen Inc. is pleased to ... Affairs Manager. , Dr. Nguyen brings to Synedgen critical ... the company as it moves forward in the FDA ... next two years. Dr. Nguyen will lead the management ... key documents that must be completed in order to ...
Breaking Biology Technology:Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 2GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 3Synedgen Announces the Appointment of Regulatory Affairs Manager 2
... 4 CV,Therapeutics, Inc. (Nasdaq: CVTX ) ... have entered into an agreement under,which Medlogics has ... develop a drug eluting stent (DES). CV Therapeutics,received ... payments,royalties and other potential payments on future sales ...
... Feb. 4 Intellisphere, publisher of,the MDNG (MD ... announced,today that it has acquired multiple titles from ... presence in several key market,segments and demonstrates its ... and education while providing new opportunities for,associates and ...
... Calif., Feb. 4 /Xinhua-PRNewswire-FirstCall/ --,(OTC Bulletin Board: KWBT) ... Mr. Wei Li, met to discuss cooperative ventures ... Health, Inc. of,Ottawa (Toronto Venture Exchange Symbol: SXS)., ... Mr. Li was Dr. Jianqiang,Zhou who is the ...
Cached Biology Technology:CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology 2CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology 3Intellisphere Announces Acquisition of Multiple Titles from Ascend Media's Healthcare Division 2Kiwa Bio-Tech Products Group Discusses Cooperative Efforts With Canadian Agricultural Ministry and Canadian Company 2Kiwa Bio-Tech Products Group Discusses Cooperative Efforts With Canadian Agricultural Ministry and Canadian Company 3
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 ... fraud case conviction losses. This figure accounts for a ... according to The Nilson Report, exceeds $11 billion globally. ... tool after a crime has occurred. Investor Mark ... polygraph expert Joe Paolella partnered to administer ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... is threatening the time-honored transmission of plant knowledge from ... and nutrition. In a novel study published online this ... Sciences, researchers report that parents, and especially mothers, who ... have healthier children, independent of other factors such as ...
... National Museum of Natural History in Washington, D.C., have ... of what they regard as one of the weirdest ... that the organism was a fungus, the scientists report ... published by the Geological Society of America. Called Prototaxites ...
... long been known that UV light can damage DNA, reducing ... resulting in the development of skin cancers. However, not much ... altered upon exposure to UV light. Now a group of ... changes in the mechanical properties of DNA upon irradiation with ...
Cached Biology News:Mother knows best: Plant knowledge key to childhood health in remote Amazon 2Prehistoric mystery organism verified as giant fungus 2Prehistoric mystery organism verified as giant fungus 3Prehistoric mystery organism verified as giant fungus 4Stretching DNA to the limit 2
... formulated to support the growth of cells ... eucalypti. The medium is a modification of ... cell lines established by Grace using this ... The basal medium, when properly supplemented, has ...
... trays and universal trays make vessel ... Shaking speed: 40 - ... amplitude Clamps for Erlenmeyer ... including Fernbach flasks Hinged ...
...
GLP expression profiling service on the Affymetrix platform. Starting material can be blood, tissue or RNA. 5 day turnaround. Standard and custom post analyses of microarray data available....
Biology Products: